Preventing progression through immunotherapy
For patients in pre- and early-malignant disease stages, such as
monoclonal gammopathy of undetermined significance (MGUS) and
smoldering multiple myeloma, current guidelines recommend monitoring
disease progression through watchful waiting. However, intervening
earlier in the disease process may improve treatment outcomes for
patients that eventually do progress to symptomatic high-risk multiple
myeloma. Our Moon Shot experts are focused on improving the
identification of patients at high-risk for progression and evaluating
the ability for immunotherapy to delay, or prevent, progression in
these patients.